Combined inhibition of topoisomerases I and II - Is this a worthwhile/feasible strategy?

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1395-1397

  Vasey, P A ^a   Kaye, S B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; IRINOTECAN; TOPOTECAN;

CANCER; CLINICAL TRIAL; CYTOTOXICITY; DNA REPLICATION; DRUG EFFICACY; EDITORIAL; ENZYME INHIBITION; FEASIBILITY STUDY; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0030727979     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.568     Document Type: Editorial

References (38)